2-amino-9-methyl-1,9-dihydro-purine-6-thione | 2382-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-amino-9-methyl-1,9-dihydro-purine-6-thione
• 英文别名: 2-Amino-9-methyl-1,9-dihydro-purin-6-thion；2-amino-9-methyl-3H-purine-6-thione
• CAS: 2382-18-5
• 化学式: C₆H₇N₅S
• 分子量: 181.221
• InChiKey: VXSWGJDRVXNRKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  70.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  9-Methylguanine 在 吡啶 、 tetraphosphorus decasulfide 作用下， 生成 2-amino-9-methyl-1,9-dihydro-purine-6-thione
  参考文献：
  名称：

  Potential Purine Antagonists. XI. Synthesis of Some 9-Aryl(alkyl)-2,6-disubstituted Purines

  摘要：

  DOI：

  10.1021/ja01544a044

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS D'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2018170306A1

  公开（公告）日：2018-09-20

  The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  该披露涉及新型脂质和相关组合物。纳米粒子组合物包括一种新型脂质以及额外的脂质，如磷脂、结构脂质和PEG脂质。纳米粒子组合物还包括治疗和/或预防措施，如RNA，在将治疗和/或预防措施传递给哺乳动物细胞或器官方面非常有用，例如，调节多肽、蛋白质或基因表达。
• [EN] PHOSPHATE AND PHOSPHONATE BASED COMPOUNDS OF 6-THIO-2'-DEOXYGUANOSINE AS ANTI-CANCER AGENTS<br/>[FR] COMPOSÉS À BASE DE PHOSPHATE ET DE PHOSPHONATE DE 6-THIO -2'-DÉSOXYGUANOSINE COMME AGENTS ANTICANCÉREUX
  申请人：MINGHUI PHARMACEUTICAL (SHANGHAI) LTD

  公开号：WO2020154917A1

  公开（公告）日：2020-08-06

  Phosphates and phosphonates compounds of 6-thio-2'-deoxyguanosine are provided. The uses and pharmaceutical compositions of these compounds are disclosed.

  提供了6-硫-2'-脱氧鸟苷的磷酸盐和膦酸盐化合物。这些化合物的用途和药用组合物已被披露。
• 2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS
  申请人：Sauve Anthony A.

  公开号：US20120108535A1

  公开（公告）日：2012-05-03

  Disclosed are halogenated 2-deoxy-lactone, 2′-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder.

  本发明涉及卤代的2-去氧内酯，2'-去氧核苷以及它们的衍生物，例如，化合物式（I）的化合物。本发明还涉及一种包含药学上可接受的载体和至少一种本发明化合物或盐的组合物，以及一种治疗异常细胞增殖、病毒感染和自身免疫性疾病等疾病的方法。
• Nucleotides for the treatment of liver cancer
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：US10030044B2

  公开（公告）日：2018-07-24

  Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, Z1, Z2, Z3, Z4, V, W, X, Ar, R1 and R2 are as described herein.

  本文提供了用于治疗肝癌（如肝细胞癌、胆管癌或胆道癌）的化合物、组合物和方法。 在某些实施方案中，公开了核苷衍生物的化合物和组合物，可单独或与其他抗癌剂联合使用。 在某些实施方案中，所述化合物为式I的核苷类似物：(I)；或其药学上可接受的盐，其中Base、Z1、Z2、Z3、Z4、V、W、X、Ar、R1和R2如本文所述。
• SCN9A antisense pain killer
  申请人：OliPass Corporation

  公开号：US11162104B2

  公开（公告）日：2021-11-02

  The current invention provides peptide nucleic acid derivatives targeting the 3′ splice site of exon 4 in the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce SCN9A mRNA splice variant(s) lacking the SCN9A exon 4 in cells, and are useful to safely treat pains or conditions involving Nav1.7 activity.

  本发明提供了靶向人 SCN9A 前 mRNA 第 4 外显子 3′剪接位点的多肽核酸衍生物。多肽核酸衍生物能有效诱导细胞中缺乏 SCN9A 第 4 号外显子的 SCN9A mRNA 剪接变体，可用于安全治疗涉及 Nav1.7 活性的疼痛或病症。